This is the authors' abstract. We don't add key points for this paper.
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kantoff et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: